WO2001088103A3 - Compositions and methods for tissue dedifferentiation and regeneration - Google Patents

Compositions and methods for tissue dedifferentiation and regeneration Download PDF

Info

Publication number
WO2001088103A3
WO2001088103A3 PCT/US2001/015582 US0115582W WO0188103A3 WO 2001088103 A3 WO2001088103 A3 WO 2001088103A3 US 0115582 W US0115582 W US 0115582W WO 0188103 A3 WO0188103 A3 WO 0188103A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
regeneration
dedifferentiation
tissue
Prior art date
Application number
PCT/US2001/015582
Other languages
French (fr)
Other versions
WO2001088103A9 (en
WO2001088103A2 (en
Inventor
Mark T Keating
Shannon J Odelberg
Kenneth D Poss
Original Assignee
Univ Utah Res Found
Mark T Keating
Shannon J Odelberg
Kenneth D Poss
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002408701A priority Critical patent/CA2408701A1/en
Priority to IL15278501A priority patent/IL152785A0/en
Priority to US10/275,828 priority patent/US20030212024A1/en
Priority to AU2001264598A priority patent/AU2001264598B2/en
Priority to AU6459801A priority patent/AU6459801A/en
Priority to EP01939035A priority patent/EP1318833A2/en
Application filed by Univ Utah Res Found, Mark T Keating, Shannon J Odelberg, Kenneth D Poss filed Critical Univ Utah Res Found
Priority to JP2001585311A priority patent/JP2004511209A/en
Publication of WO2001088103A2 publication Critical patent/WO2001088103A2/en
Publication of WO2001088103A9 publication Critical patent/WO2001088103A9/en
Priority to US10/302,812 priority patent/US20040087016A1/en
Publication of WO2001088103A3 publication Critical patent/WO2001088103A3/en
Priority to US11/880,435 priority patent/US20080227738A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1323—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from skeletal muscle cells

Abstract

The present invention is directed to methods and compositions to induce cellular dedifferentiation and tissue regeneration in vitro and in vivo.
PCT/US2001/015582 2000-05-12 2001-05-14 Compositions and methods for tissue dedifferentiation and regeneration WO2001088103A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IL15278501A IL152785A0 (en) 2000-05-12 2001-05-14 Compositions and methods for cell dedifferentiation and tissue regeneration
US10/275,828 US20030212024A1 (en) 2000-05-12 2001-05-14 Compositions and methods for cell dedifferentiation and tissue regeneration
AU2001264598A AU2001264598B2 (en) 2000-05-12 2001-05-14 Compositions and methods for tissue dedifferentiation and regeneration
AU6459801A AU6459801A (en) 2000-05-12 2001-05-14 Compositions and methods for cell dedifferentiation and tissue regeneration
EP01939035A EP1318833A2 (en) 2000-05-12 2001-05-14 Compositions and methods for cell dedifferentiation and tissue regeneration
CA002408701A CA2408701A1 (en) 2000-05-12 2001-05-14 Compositions and methods for tissue dedifferentiation and regeneration
JP2001585311A JP2004511209A (en) 2000-05-12 2001-05-14 Compositions and methods for cell dedifferentiation and tissue regeneration
US10/302,812 US20040087016A1 (en) 2000-05-12 2002-11-22 Compositions and methods for cell dedifferentiation and tissue regeneration
US11/880,435 US20080227738A1 (en) 2000-05-12 2007-07-20 Compositions and methods for cell dedifferentiation and tissue regeneration

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US20408200P 2000-05-12 2000-05-12
US20408100P 2000-05-12 2000-05-12
US20408000P 2000-05-12 2000-05-12
US60/204,081 2000-05-12
US60/204,082 2000-05-12
US60/204,080 2000-05-12

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/275,828 A-371-Of-International US20030212024A1 (en) 2000-05-12 2001-05-14 Compositions and methods for cell dedifferentiation and tissue regeneration
US10/302,812 Continuation-In-Part US20040087016A1 (en) 2000-05-12 2002-11-22 Compositions and methods for cell dedifferentiation and tissue regeneration

Publications (3)

Publication Number Publication Date
WO2001088103A2 WO2001088103A2 (en) 2001-11-22
WO2001088103A9 WO2001088103A9 (en) 2002-05-23
WO2001088103A3 true WO2001088103A3 (en) 2003-03-13

Family

ID=27394620

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/015582 WO2001088103A2 (en) 2000-05-12 2001-05-14 Compositions and methods for tissue dedifferentiation and regeneration

Country Status (7)

Country Link
US (1) US20030212024A1 (en)
EP (1) EP1318833A2 (en)
JP (1) JP2004511209A (en)
AU (2) AU6459801A (en)
CA (1) CA2408701A1 (en)
IL (1) IL152785A0 (en)
WO (1) WO2001088103A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087016A1 (en) * 2000-05-12 2004-05-06 University Of Utah Research Foundation Compositions and methods for cell dedifferentiation and tissue regeneration
CA2469370C (en) * 2001-12-07 2014-07-08 Macropore Biosurgery, Inc. Adipose-derived cell processing unit
US9597395B2 (en) 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US20050095228A1 (en) 2001-12-07 2005-05-05 Fraser John K. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
US7771716B2 (en) 2001-12-07 2010-08-10 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of musculoskeletal disorders
US7651684B2 (en) * 2001-12-07 2010-01-26 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in augmenting autologous fat transfer
US7595043B2 (en) * 2001-12-07 2009-09-29 Cytori Therapeutics, Inc. Method for processing and using adipose-derived stem cells
US8404229B2 (en) * 2001-12-07 2013-03-26 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to treat acute tubular necrosis
US20050048036A1 (en) * 2001-12-07 2005-03-03 Hedrick Marc H. Methods of using regenerative cells in the treatment of inherited and acquired disorders of the bone, bone marrow, liver, and other tissues
US7585670B2 (en) * 2001-12-07 2009-09-08 Cytori Therapeutics, Inc. Automated methods for isolating and using clinically safe adipose derived regenerative cells
US20050008626A1 (en) * 2001-12-07 2005-01-13 Fraser John K. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
WO2006075986A1 (en) * 2005-01-10 2006-07-20 Macropore Biosurgery, Inc. Devices and methods for monitoring, managing, and servicing medical devices
US20060204556A1 (en) * 2001-12-07 2006-09-14 Cytori Therapeutics, Inc. Cell-loaded prostheses for regenerative intraluminal applications
US7514075B2 (en) * 2001-12-07 2009-04-07 Cytori Therapeutics, Inc. Systems and methods for separating and concentrating adipose derived stem cells from tissue
US8105580B2 (en) 2001-12-07 2012-01-31 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to promote wound healing
US20050282733A1 (en) * 2002-06-27 2005-12-22 Prins Johannes B Differentiation modulating agents and uses therefor
WO2004092325A2 (en) * 2002-12-24 2004-10-28 Board Of Regents, The University Of Texas System Screening methods using zebrafish to identify thrombotic and anti-thrombotic compounds and genes
US7374760B2 (en) 2003-05-15 2008-05-20 The University Of Chicago Methods and compositions for nerve regeneration
US7875272B2 (en) 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
US7413734B2 (en) 2003-06-27 2008-08-19 Ethicon, Incorporated Treatment of retinitis pigmentosa with human umbilical cord cells
US8790637B2 (en) 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US8491883B2 (en) 2003-06-27 2013-07-23 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US8518390B2 (en) 2003-06-27 2013-08-27 Advanced Technologies And Regenerative Medicine, Llc Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
US7592177B2 (en) 2003-11-10 2009-09-22 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
US20050232905A1 (en) * 2004-03-26 2005-10-20 Yeh Edward T Use of peripheral blood cells for cardiac regeneration
AU2005322068B2 (en) 2004-12-23 2011-09-01 Ethicon Incorporated Treatment of stroke and other acute neural degenerative disorders using postpartum derived cells
PL1831356T3 (en) 2004-12-23 2017-07-31 DePuy Synthes Products, Inc. Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
JP5017253B2 (en) 2005-03-31 2012-09-05 ステムニオン，インコーポレイテッド Amnion-derived cell composition, preparation method and use thereof
WO2007070870A1 (en) 2005-12-16 2007-06-21 Ethicon, Inc. Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation
WO2007073552A1 (en) 2005-12-19 2007-06-28 Ethicon, Inc. In vitro expansion of postpartum derived cells in roller bottles
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
GB0613031D0 (en) * 2006-06-30 2006-08-09 Renovo Ltd Medicaments
MX2010003606A (en) 2007-10-01 2010-07-02 Isis Pharmaceuticals Inc Antisense modulation of fibroblast growth factor receptor 4 expression.
UA99152C2 (en) 2007-10-05 2012-07-25 Этикон, Инкорпорейтед Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells
US8236538B2 (en) 2007-12-20 2012-08-07 Advanced Technologies And Regenerative Medicine, Llc Methods for sterilizing materials containing biologically active agents
WO2010021993A1 (en) 2008-08-19 2010-02-25 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease
US10179900B2 (en) 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
CA2747794C (en) 2008-12-19 2018-10-30 Advanced Technologies And Regenerative Medicine, Llc Treatment of lung and pulmonary diseases and disorders
BRPI1013409A2 (en) 2009-03-26 2018-01-16 Advanced Tech And Regenerative Medicine Llc human umbilical cord tissue cells as therapy for alzheimer's disease
JP5917392B2 (en) 2009-05-01 2016-05-11 ビミニ テクノロジーズ リミテッド ライアビリティ カンパニー Systems, methods and compositions for optimizing tissue and cell-enriched grafts
US8735116B2 (en) 2010-09-13 2014-05-27 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration High-density spot seeding for tissue model formation
CA2839437A1 (en) 2011-06-16 2012-12-20 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
MX362198B (en) 2011-12-23 2019-01-08 Depuy Synthes Products Llc Detection of human umbilical cord tissue-derived cells.
JP2020502218A (en) 2016-12-21 2020-01-23 メレオ バイオファーマ ３ リミテッド Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
JP2022535747A (en) * 2019-05-28 2022-08-10 ケース ウエスタン リザーブ ユニバーシティ Compositions and methods for preserving DNA methylation
CN116555346B (en) * 2023-07-05 2023-09-01 中山大学 Method for promoting growth of grass carp by adopting carbon nanotube gene carrier delivery system

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000017321A2 (en) * 1998-09-18 2000-03-30 Massachusetts Institute Of Technology Use of growth factors and hormones for expansion of mammalian cells and tissue engineering

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4528265A (en) * 1982-05-11 1985-07-09 Becker Robert O Processes and products involving cell modification
DE69434739T2 (en) * 1993-08-26 2007-05-10 Genetics Institute, LLC, Cambridge Human bone morphogenetic proteins for use in neuronal degeneration
TW509699B (en) * 1998-09-24 2002-11-11 Chugau Pharmaceutical Co Ltd Ethylamine derivatives
US6897061B1 (en) * 2000-06-16 2005-05-24 Spinal Cord Society Transdifferentiation of glial cells
US7425448B2 (en) * 2001-07-12 2008-09-16 Geron Corporation Cardiomyocyte precursors from human embryonic stem cells
US20040014209A1 (en) * 2002-01-23 2004-01-22 Lassar Andrew B. Compositions and methods for modulating cell differentiation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000017321A2 (en) * 1998-09-18 2000-03-30 Massachusetts Institute Of Technology Use of growth factors and hormones for expansion of mammalian cells and tissue engineering

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DEL RIO-TSONIS KATIA ET AL: "Regulation of lens regeneration by fibroblast growth factor receptor 1.", DEVELOPMENTAL DYNAMICS, vol. 213, no. 1, 1998, pages 140 - 146, XP002204581, ISSN: 1058-8388 *
D'JAMOOS CHRISTOPHER A ET AL: "Fibroblast growth factor receptors regulate the ability for hindlimb regeneration in Xenopus laevis.", WOUND REPAIR AND REGENERATION, vol. 6, no. 4, July 1998 (1998-07-01), pages S388 - S397, XP001070883, ISSN: 1067-1927 *
ENDO TAKESHI ET AL: "Reversal of myogenic terminal differentiation by SV40 large T antigen results in mitosis and apoptosis.", JOURNAL OF CELL SCIENCE, vol. 111, no. 8, April 1998 (1998-04-01), pages 1081 - 1093, XP002204583, ISSN: 0021-9533 *
GRINSPAN JUDITH B ET AL: "Trophic effects of basic fibroblast growth factor (bFGF) on differentiated oligodendroglia: A mechanism for regeneration of the oligodendroglial lineage.", JOURNAL OF NEUROSCIENCE RESEARCH, vol. 36, no. 6, 1993, pages 672 - 680, XP001070906, ISSN: 0360-4012 *
NAVRE M ET AL: "DIFFERENTIAL EFFECTS OF FIBROBLAST GROWTH FACTOR AND TUMOR PROMOTERS ON THE INITIATION AND MAINTENANCE OF ADIPOCYTE DIFFERENTIATION", JOURNAL OF CELL BIOLOGY, vol. 109, no. 4 PART 1, 1989, pages 1857 - 1864, XP001069842, ISSN: 0021-9525 *
POSS KENNETH D ET AL: "Roles for Fgf signaling during zebrafish fin regeneration.", DEVELOPMENTAL BIOLOGY, vol. 222, no. 2, 15 June 2000 (2000-06-15), pages 347 - 358, XP002204584, ISSN: 0012-1606 *
ROSANIA GUSTAVO R ET AL: "Myoseverin, a microtubule-binding molecule with novel cellular effects.", NATURE BIOTECHNOLOGY, vol. 18, no. 3, March 2000 (2000-03-01), pages 304 - 308, XP002204582, ISSN: 1087-0156 *
ZENJARI CHAFIKA ET AL: "Experimental evidence for FGF-1 control of blastema cell proliferation during limb regeneration of the amphibian Pleurodeles waltl.", INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY, vol. 40, no. 5, 1996, pages 965 - 971, XP001070913, ISSN: 0214-6282 *

Also Published As

Publication number Publication date
WO2001088103A9 (en) 2002-05-23
US20030212024A1 (en) 2003-11-13
AU6459801A (en) 2001-11-26
EP1318833A2 (en) 2003-06-18
IL152785A0 (en) 2003-06-24
CA2408701A1 (en) 2001-11-22
JP2004511209A (en) 2004-04-15
AU2001264598B2 (en) 2006-07-06
WO2001088103A2 (en) 2001-11-22

Similar Documents

Publication Publication Date Title
WO2001088103A3 (en) Compositions and methods for tissue dedifferentiation and regeneration
AU2001276048A1 (en) Rapid-melt semi-solid compositions, methods of making same and methods of using same
AU2001279284A1 (en) Rapid-melt semi-solid compositions, methods of making same and methods of using same
AU2001245437A1 (en) Lightweight methods and compositions for well treating
AU2778801A (en) Antisense compositions and methods
AU6147401A (en) Compositions and methods for the treatment of cancer
AU2001268126A1 (en) Compositions, kits, and methods for promoting defined health benefits
EP1438062A4 (en) Methods and compositions for treating dermal lesions
AU2001280604A1 (en) Compositions comprising icariside i and anhydroicaritin and methods for making the same
IL150219A0 (en) Mulch composition and methods for the preparation and use thereof
AU2001260847A1 (en) Compositions isolated from skin cells and methods for their use
IL144517A0 (en) Compositions and methods for treating cataracts
AU2002213114A1 (en) Compositions and methods for reducing gnrh-induced bone loss
EP1298193A4 (en) Cold-resistant fat composition and process for producing the same
ZA200302014B (en) Methods and compositions for promoting the maturation of monocytes.
AU2001271266A1 (en) Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
AU2001294820A1 (en) Methods for in vivo reduction of free radical levels and compositions useful therefor
AU3837201A (en) Low tack cosmetic composition sticks
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
AU2001268232A1 (en) Compositions, methods, and kits relating to resistin-like molecules
EP1409507A4 (en) Compositions, methods and kits relating to remodelin
AU2002353078A8 (en) Tissue graft compositions and methods for producing same
HUP0303936A3 (en) Novel composition and use
WO2002024179A3 (en) Method for reducing toxicity of combined chemotherapies
HK1062139A1 (en) Compositions for improving lipids in blood

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGE 1, DESCRIPTION, REPLACED BY A NEW PAGE 1 (WITH AN UPDATED VERSION OF THE PAMPHLET FRONT PAGE)

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 152785

Country of ref document: IL

Ref document number: 2408701

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001264598

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001939035

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10275828

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001939035

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)